Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 ravulizumab versus placebo in complement-inhibitor-naive adults with generalized myasthenia gravis
NL-OMON52651Phase 3Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of ravulizumab, sponsored by Alexion Pharmaceuticals. Started Jan 2020; status: recruiting.
02
Drugs
ravulizumab
Beyond the preview
Go deeper on NL-OMON52651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52651.